ARTICLE | Clinical News
Oxtellar XR oxcarbazepine regulatory update
October 29, 2012 7:00 AM UTC
Supernus said FDA approved an NDA for Oxtellar XR oxcarbazepine as an adjunctive therapy for epilepsy in adults and children ages 6-17 years old. The company plans to launch the oral, once-daily extended-release formulation of oxcarbazepine in 1Q13. The company is not disclosing pricing details. ...